实现免疫生物标志物诊断
合集下载
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
When using our slides, please retain the source attribution:
Slide credit: clinicaloptions.com
These slides may not be published, posted online, or used in commercial presentations without permission. Please contact permissions@clinicaloptions.com for details
Scott Kopetz, MD, PhD, FACP, has disclosed that he has ownership interest in Navire and has received consulting fees from Amal Therapeutics, Amgen, Boehringer Ingelheim, Holy Stone, Lilly, Merck, Navire, Novartis, Roche, and Symphogen.
Supported by educational grants from Bristol-Myers Squibb and Foundation Medicine.
About These Slides
Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients
David R. Spigel, MD
Chief Scientific Officer Director, Lung Cancer Research Program Sarah Cannon Research Institute Nashville, Tennessee
Faculty Dቤተ መጻሕፍቲ ባይዱsclosures
Expert Faculty
Scott Kopetz, MD, PhD, FACP
Associate Professor, Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jason N. Rosenbaum, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, and Genentech.
Faculty Disclosures
David R. Spigel, MD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Aeglea, Amgen, ARMO, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Evelo, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Illumina, Ipsen, Lilly, Merck, Millennium, Moderna Therapeutics, Nektar, Novartis, PharmaMar, Pfizer, Precision Oncology, and Takeda and funds for research support granted to his institution from AbbVie, Acerta, Astellas, AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb, Celgene, CellDex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Foundation Medicine, G1 Therapeutics, GlaxoSmithKline, GRAIL, Lilly, Merck, Neon Therapeutics, Nektar, Novartis, Oncogenex, Pfizer, Takeda, Tesaro, and Transgene.
Implementing Immune-Biomarker Diagnostics
Jason N. Rosenbaum, MD
Assistant Professor Department of Pathology and Laboratory Medicine University of Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
Jason N. Rosenbaum, MD
Assistant Professor, Department of Pathology and Laboratory Medicine University of Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
Slide credit: clinicaloptions.com
These slides may not be published, posted online, or used in commercial presentations without permission. Please contact permissions@clinicaloptions.com for details
Scott Kopetz, MD, PhD, FACP, has disclosed that he has ownership interest in Navire and has received consulting fees from Amal Therapeutics, Amgen, Boehringer Ingelheim, Holy Stone, Lilly, Merck, Navire, Novartis, Roche, and Symphogen.
Supported by educational grants from Bristol-Myers Squibb and Foundation Medicine.
About These Slides
Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients
David R. Spigel, MD
Chief Scientific Officer Director, Lung Cancer Research Program Sarah Cannon Research Institute Nashville, Tennessee
Faculty Dቤተ መጻሕፍቲ ባይዱsclosures
Expert Faculty
Scott Kopetz, MD, PhD, FACP
Associate Professor, Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jason N. Rosenbaum, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, and Genentech.
Faculty Disclosures
David R. Spigel, MD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Aeglea, Amgen, ARMO, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Evelo, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Illumina, Ipsen, Lilly, Merck, Millennium, Moderna Therapeutics, Nektar, Novartis, PharmaMar, Pfizer, Precision Oncology, and Takeda and funds for research support granted to his institution from AbbVie, Acerta, Astellas, AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb, Celgene, CellDex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Foundation Medicine, G1 Therapeutics, GlaxoSmithKline, GRAIL, Lilly, Merck, Neon Therapeutics, Nektar, Novartis, Oncogenex, Pfizer, Takeda, Tesaro, and Transgene.
Implementing Immune-Biomarker Diagnostics
Jason N. Rosenbaum, MD
Assistant Professor Department of Pathology and Laboratory Medicine University of Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
Jason N. Rosenbaum, MD
Assistant Professor, Department of Pathology and Laboratory Medicine University of Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania